On March 2, 2022 Nuvalent, Inc. (Nasdaq: NUVL), a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, reported that James Porter, Ph.D., Chief Executive Officer, will participate in a virtual panel titled, "Lung Cancer Panel," during the Cowen 42nd Annual Healthcare Conference on Wednesday, March 9, 2022, at 9:10 a.m. ET (Press release, Nuvalent, MAR 2, 2022, View Source [SID1234609385]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast will be available in the investor section of the company’s website at www.nuvalent.com, and archived for 30 days following the presentation.